Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Norman Wolmark, MD
NSABP Foundation Inc
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
36 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Montreal Hospital Group
Montreal, Quebec, Canada
- Clearview Cancer Institute- Huntsville
Huntsville, Alabama, United States
- Kaiser Permanente-San Diego
San Diego, California, United States
- Kaiser Permanente-Vallejo
Vallejo, California, United States
- Ccop, Colorado Cancer Research Program, Inc.
Denver, Colorado, United States
- Baptist Regional Cancer Institute
Jacksonville, Florida, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Ccop, Central Illinois
Springfield, Illinois, United States
- Ccop, Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States
- University of Iowa
Iowa City, Iowa, United States
- Nortonhealtcare Inc.
Louisville, Kentucky, United States
- Ccop, Grand Rapids Clnical Oncology Program
Grand Rapids, Michigan, United States
- Ccop, Michigan Cancer Research Consortium
Grosse Pointe Woods, Michigan, United States
- Ccop, Kalamazoo, Mi
Kalamazoo, Michigan, United States
- Michigan State University - Breslin Cancer Center
Lansing, Michigan, United States
- Ccop, Metro-Minnesota
Minneapolis, Minnesota, United States
- Ccop, Cancer Research for the Ozarks
Springfield, Missouri, United States
- Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- University Hospital and Medical Center - Suny
Stony Brook, New York, United States
- Ccop, Southeast Cancer Control Consortium
Charlotte, North Carolina, United States
- East Carolina University
Greenville, North Carolina, United States
- Aultman Hospital
Canton, Ohio, United States
- Case Western Reserve/university Hospitals-Ireland Cancer Cntr.
Cleveland, Ohio, United States
- Ccop, Dayton, Oh
Dayton, Ohio, United States
- Ccop, Columbia River Oncology
Portland, Oregon, United States
- Albert Einstein Healthcare Network
Philadelphia, Pennsylvania, United States
- Kimmel Cancer Center at Jefferson
Philadelphia, Pennsylvania, United States
- Allegheny General Hospital/allegheny-Singer Research Institute
Pittsburgh, Pennsylvania, United States
- Nsabp Foundation, Inc.
Pittsburgh, Pennsylvania, United States
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
- Mercy Hospital
Scranton, Pennsylvania, United States
- Ccop, Upstate Carolina
Spartanburg, South Carolina, United States
- Joe Arrington Cancer Research & Treatment Center
Lubbock, Texas, United States
- Ccop, Scott and White Memorial Hospital
Temple, Texas, United States
- Mbccop, Virginia Commonwealth University
Richmond, Virginia, United States
- Ccop, Marshfield Clinic
Marshfield, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2007
- Primary completion
- 31 Dec 2009
- Completion
- 31 May 2014
- Last update posted
- 25 Oct 2021
- Registered enrollment
- 105
- Registry id
- NCT00464646
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.